CL2019003161A1 - Métodos de tratamiento selectivo del asma usando antagonistas de il-17. - Google Patents
Métodos de tratamiento selectivo del asma usando antagonistas de il-17.Info
- Publication number
- CL2019003161A1 CL2019003161A1 CL2019003161A CL2019003161A CL2019003161A1 CL 2019003161 A1 CL2019003161 A1 CL 2019003161A1 CL 2019003161 A CL2019003161 A CL 2019003161A CL 2019003161 A CL2019003161 A CL 2019003161A CL 2019003161 A1 CL2019003161 A1 CL 2019003161A1
- Authority
- CL
- Chile
- Prior art keywords
- antagonists
- selective
- treatment methods
- asthma treatment
- asthma
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762501806P | 2017-05-05 | 2017-05-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019003161A1 true CL2019003161A1 (es) | 2020-02-07 |
Family
ID=62245372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019003161A CL2019003161A1 (es) | 2017-05-05 | 2019-11-04 | Métodos de tratamiento selectivo del asma usando antagonistas de il-17. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10676522B2 (https=) |
| EP (1) | EP3619536A1 (https=) |
| JP (1) | JP2020518604A (https=) |
| KR (1) | KR20190142398A (https=) |
| CN (1) | CN110582702A (https=) |
| AU (1) | AU2018263159A1 (https=) |
| BR (1) | BR112019023141A2 (https=) |
| CA (1) | CA3062179A1 (https=) |
| CL (1) | CL2019003161A1 (https=) |
| MX (1) | MX2019013160A (https=) |
| RU (1) | RU2019139387A (https=) |
| TW (1) | TW201842933A (https=) |
| WO (1) | WO2018203289A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3689907A1 (en) * | 2019-01-31 | 2020-08-05 | Numab Therapeutics AG | Antibodies targeting il-17a and methods of use thereof |
| CN115362173A (zh) * | 2020-04-17 | 2022-11-18 | 伊莱利利公司 | 呼吸系统疾病的治疗 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0308324D0 (en) | 2003-04-10 | 2003-05-14 | Piezoptic Ltd | A chemical sensing device |
| CN1898564A (zh) * | 2003-12-24 | 2007-01-17 | 惠氏公司 | 治疗哮喘的方法 |
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| GB0425569D0 (en) | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Biological products |
| EP1963368B3 (en) | 2005-12-13 | 2020-06-10 | Eli Lilly And Company | Anti-il-17 antibodies |
| GB0612928D0 (en) | 2006-06-29 | 2006-08-09 | Ucb Sa | Biological products |
| US7767206B2 (en) | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
| BRPI0906261A2 (pt) | 2008-03-31 | 2015-07-07 | Genentech Inc | "métodos de diagnóstico de um subtipo de asma em uma amostra de paciente, usos de um agente terapêutico e kits de diagnóstico de um subtipo de asma em uma amostra de paciente" |
| NZ591484A (en) | 2008-09-29 | 2012-09-28 | Roche Glycart Ag | Antibodies against human il 17 and uses thereof |
| LT2953969T (lt) | 2013-02-08 | 2019-12-10 | Novartis Ag | Anti-il-17a antikūnai ir jų panaudojimas autoimuninių ir uždegiminių ligų gydymui |
| AR098155A1 (es) * | 2013-10-23 | 2016-05-04 | Genentech Inc | Métodos para diagnosticar y tratar trastornos eosinofílicos |
| WO2015191783A2 (en) * | 2014-06-10 | 2015-12-17 | Abbvie Inc. | Biomarkers for inflammatory disease and methods of using same |
| CN115957326A (zh) * | 2014-09-10 | 2023-04-14 | 诺华股份有限公司 | 使用il-17拮抗剂抑制银屑病关节炎患者的结构损伤进展 |
| GB201508832D0 (en) | 2015-05-22 | 2015-07-01 | Novartis Ag | A method for detecting an analyte |
-
2018
- 2018-05-03 TW TW107114983A patent/TW201842933A/zh unknown
- 2018-05-03 US US15/969,952 patent/US10676522B2/en active Active
- 2018-05-04 CN CN201880029544.7A patent/CN110582702A/zh active Pending
- 2018-05-04 AU AU2018263159A patent/AU2018263159A1/en not_active Abandoned
- 2018-05-04 JP JP2019560115A patent/JP2020518604A/ja active Pending
- 2018-05-04 KR KR1020197035578A patent/KR20190142398A/ko not_active Abandoned
- 2018-05-04 RU RU2019139387A patent/RU2019139387A/ru not_active Application Discontinuation
- 2018-05-04 MX MX2019013160A patent/MX2019013160A/es unknown
- 2018-05-04 WO PCT/IB2018/053106 patent/WO2018203289A1/en not_active Ceased
- 2018-05-04 EP EP18727435.2A patent/EP3619536A1/en not_active Withdrawn
- 2018-05-04 CA CA3062179A patent/CA3062179A1/en not_active Abandoned
- 2018-05-04 BR BR112019023141-2A patent/BR112019023141A2/pt not_active Application Discontinuation
-
2019
- 2019-11-04 CL CL2019003161A patent/CL2019003161A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN110582702A (zh) | 2019-12-17 |
| CA3062179A1 (en) | 2018-11-08 |
| WO2018203289A1 (en) | 2018-11-08 |
| TW201842933A (zh) | 2018-12-16 |
| US20180319881A1 (en) | 2018-11-08 |
| AU2018263159A1 (en) | 2019-11-07 |
| MX2019013160A (es) | 2020-02-05 |
| EP3619536A1 (en) | 2020-03-11 |
| JP2020518604A (ja) | 2020-06-25 |
| US10676522B2 (en) | 2020-06-09 |
| BR112019023141A2 (pt) | 2020-07-28 |
| KR20190142398A (ko) | 2019-12-26 |
| RU2019139387A (ru) | 2021-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019011995A2 (es) | Procesos para la producción de linfocitos infiltrantes de tumores y usos de ellos en inmunoterapia | |
| MX2024013963A (es) | Un antagonista de il-4r util para el tratamiento o la prevencion del asma | |
| MX2017011834A (es) | Macrociclos peptidomimeticos y usos de los mismos. | |
| MX2019014009A (es) | Metodos mejorados para la elaboracion de terapias celulares adoptivas. | |
| MX2024000348A (es) | Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica. | |
| DOP2017000271A (es) | Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t | |
| MX2017008875A (es) | Anticuerpos biespecificos contra cd3 y cd20. | |
| CL2015002807A1 (es) | Terapia de combinación | |
| GT201700167A (es) | Terapias de combinación para el tratamiento de cánceres. | |
| MX2019008085A (es) | Antagonistas de activina-actrii y usos para tratar transtornos oseos y otros. | |
| MX2016005159A (es) | Metodos de diagnostico y tratamiento de trastornos eosinofilicos. | |
| MX2015010724A (es) | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. | |
| MX370664B (es) | Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos. | |
| EA033374B1 (ru) | Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения | |
| CL2015002941A1 (es) | Usos terapéuticos de empaglifozina | |
| BR112017005598A2 (pt) | macrociclos peptidomiméticos e usos dos mesmos | |
| AR092899A1 (es) | Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion | |
| MX2021008305A (es) | Anticuerpos anti-cd40 para el uso en el tratamiento de hidradenitis supurativa. | |
| AR101476A1 (es) | Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk) | |
| CL2020001123A1 (es) | Anticuerpos anti-cd40 para el uso en el tratamiento del síndrome de sjögren. | |
| UY35438A (es) | Procedimiento para preparar inhibidores de la glucosilceramida sintasa. | |
| UY34991A (es) | Inhibidores de la beta-secretasa | |
| CL2019003161A1 (es) | Métodos de tratamiento selectivo del asma usando antagonistas de il-17. | |
| MX2017001566A (es) | Terapias antibioticas peptidicas derivadas del bufalo de agua. | |
| MX375318B (es) | Formas de dosificación y usos terapéuticos de l-4-cloro quinurenina.. |